Blum, Kristie A.;
Polley, Mei‐Yin;
Jung, Sin‐Ho;
Dockter, Travis J.;
Anderson, Sarah;
Hsi, Eric D.;
Wagner‐Johnston, Nina;
Christian, Beth;
Atkins, Jim;
Cheson, Bruce D.;
Leonard, John P.;
Bartlett, Nancy L.
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance)
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance)
Beteiligte:
Blum, Kristie A.;
Polley, Mei‐Yin;
Jung, Sin‐Ho;
Dockter, Travis J.;
Anderson, Sarah;
Hsi, Eric D.;
Wagner‐Johnston, Nina;
Christian, Beth;
Atkins, Jim;
Cheson, Bruce D.;
Leonard, John P.;
Bartlett, Nancy L.
Beschreibung:
<jats:sec><jats:title>Background</jats:title><jats:p>This multicenter, randomized phase 2 trial evaluated complete responses (CRs), efficacy, and safety with ofatumumab and bendamustine and with ofatumumab, bendamustine, and bortezomib in patients with untreated, high‐risk follicular lymphoma (FL).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients with grade 1 to 3a FL and either a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 with 1 lymph node >6 cm or an FLIPI score of 3 to 5 were randomized to arm A (ofatumumab, bendamustine, and maintenance ofatumumab) or to arm B (ofatumumab, bendamustine, bortezomib, and maintenance ofatumumab and bortezomib).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>One hundred twenty‐eight patients (66 in arm A and 62 in arm B) received treatment. The median age was 61 years, and 61% had disease >6 cm; 29% had an FLIPI score of 2, and 71% had an FLIPI score of 3 to 5. In arm A, 86% completed induction, and 64% completed maintenance. In arm B, 66% and 52% completed induction and maintenance, respectively. Dose modifications were required in 65% and 89% in arms A and B, respectively. Clinically significant grade 3 to 4 toxicities included neutropenia (A, 36%; B, 31%), nausea/vomiting (A, 0%; B, 8%), diarrhea (A, 5%; B, 11%), and sensory neuropathy (A, 0%; B, 5%). The estimated CR rates were 62% (95% confidence interval [CI], 50%‐74%) and 60% (95% CI, 47%‐72%) in arms A and B, respectively (<jats:italic>P</jats:italic> = .68). With a median follow‐up of 3.3 years, the estimated 2‐year progression‐free survival (PFS) and overall survival (OS) rates were 80% and 97%, respectively, for arm A and 76% and 91%, respectively, for arm B.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The CR rates, PFS, and OS were not improved with the addition of bortezomib to ofatumumab and bendamustine in patients with high‐risk FL. Although grade 3 to 4 toxicities were similar, more patients treated with bortezomib required dose modifications and early discontinuation.</jats:p></jats:sec>